Published in: Molecular Cancer Therapeutics
Authors: Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos, and John T. Schiller
The research group studied a novel recombinant papillomavirus-like particle (VLP) drug conjugate and its initial evaluation as a potential treatment for primary uveal melanoma. Laser was used for evaluating tumor-specific targeting and cellular toxicity of their novel IRDye 700DX-conjugated papillomavirus-like particle (AU-011) in vitro using human cancer cell lines. This was complemented with in vivo experiments.
